Effects of alginate inclusion on the vector properties of chitosan-based nanoparticles

被引:115
作者
Douglas, Kimberly L.
Piecirillo, Ciriaco A.
Tabrizian, Maryam
机构
[1] McGill Univ, Dept Biomed Engn, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada
[3] McGill Univ, Fac Dent, Ctr Biorecognit & Biosensors, Montreal, PQ H3A 2B4, Canada
基金
加拿大自然科学与工程研究理事会; 加拿大健康研究院;
关键词
chitosan; alginate; nanoparticles; cell viability; in vitro transfection;
D O I
10.1016/j.jconrel.2006.08.021
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Chitosan nanoparticles have shown considerable promise as gene vectors but do not mediate transfection with satisfactory efficiency. To improve upon the transfection efficiency of chitosan, we approached the development of alginatc-chitosan nanoparticles with the goals of maintaining low toxicity and biocompatibility. Through ionic gelation, particles were formed with a mean Z-average diameter of 157 nm and a zeta potential of +32 mV. Competition binding assays indicated that the presence of alginate reduces the strength of interaction between chitosan and DNA, contributing to improved transfection. Cell viability assays indicated that nanoparticles exhibit the same low toxicity as chitosan, and significantly reduced toxicity compared to a commercial liposome formulation. As well, complexation with nanoparticles maintained DNA integrity and protected it from nuclease degradation better than chitosan alone. Alginate-chitosan nanoparticles were able to mediate transfection of 293T cells four times that achieved by chitosan nanoparticles; at 48 h, the transfection efficiency was as high as with Lipofectamine (TM), with significantly reduced cytotoxicity. Overall, alginate inclusion improved the vector properties of chitosan-based nanoparticles, demonstrating superior transfection ability while maintaining biocompatibility and low toxicity. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:354 / 361
页数:8
相关论文
共 31 条
[1]   Recent advances on chitosan-based micro- and nanoparticles in drug delivery [J].
Agnihotri, SA ;
Mallikarjuna, NN ;
Aminabhavi, TM .
JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :5-28
[2]   Synthesis of poly(β-amino ester)s optimized for highly effective gene delivery [J].
Akinc, A ;
Anderson, DG ;
Lynn, DM ;
Langer, R .
BIOCONJUGATE CHEMISTRY, 2003, 14 (05) :979-988
[3]   Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer [J].
Boeckle, S ;
von Gersdorff, K ;
van der Piepen, S ;
Culmsee, C ;
Wagner, E ;
Ogris, M .
JOURNAL OF GENE MEDICINE, 2004, 6 (10) :1102-1111
[4]   In vitro myotoxicity of selected cationic macromolecules used in non-viral gene delivery [J].
Brazeau, GA ;
Attia, S ;
Poxon, S ;
Hughes, JA .
PHARMACEUTICAL RESEARCH, 1998, 15 (05) :680-684
[5]   Reversibly stable thiopolyplexes for intracellular delivery of genes [J].
Cavallaro, Gennara ;
Campisi, Monica ;
Licciardi, Mariano ;
Ogris, Manfred ;
Giammona, Gaetano .
JOURNAL OF CONTROLLED RELEASE, 2006, 115 (03) :322-334
[6]   Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles [J].
Corsi, K ;
Chellat, F ;
Yahia, L ;
Fernandes, JC .
BIOMATERIALS, 2003, 24 (07) :1255-1264
[7]   DNA-polycation complexation and polyplex stability in the presence of competing polyanions [J].
Danielsen, S ;
Maurstad, G ;
Stokke, BT .
BIOPOLYMERS, 2005, 77 (02) :86-97
[8]   Effect of experimental parameters on the formation of alginate-chitosan nanoparticles and evaluation of their potential application as DNA carrier [J].
Douglas, KL ;
Tabrizian, M .
JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 2005, 16 (01) :43-56
[9]   Chitosan-based vector/DNA complexes for gene delivery: Biophysical characteristics and transfection ability [J].
Erbacher, P ;
Zou, SM ;
Bettinger, T ;
Steffan, AM ;
Remy, JS .
PHARMACEUTICAL RESEARCH, 1998, 15 (09) :1332-1339
[10]   Galactosylated low molecular weight chitosan as DNA carrier for hepatocyte-targeting [J].
Gao, SY ;
Chen, JN ;
Xu, XR ;
Ding, Z ;
Yang, YH ;
Hua, ZC ;
Zhang, JF .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 255 (1-2) :57-68